These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31218354)

  • 21. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
    Bonaca MP; Bhatt DL; Braunwald E; Cohen M; Steg PG; Storey RF; Held P; Jensen EC; Sabatine MS
    Am Heart J; 2014 Apr; 167(4):437-444.e5. PubMed ID: 24655690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
    Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
    J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.
    Bonaca MP; Bhatt DL; Oude Ophuis T; Steg PG; Storey R; Cohen M; Kuder J; Im K; Magnani G; Budaj A; Theroux P; Hamm C; Špinar J; Kiss RG; Dalby AJ; Medina FA; Kontny F; Aylward PE; Jensen EC; Held P; Braunwald E; Sabatine MS
    JAMA Cardiol; 2016 Jul; 1(4):425-32. PubMed ID: 27438319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
    Easton JD; Aunes M; Albers GW; Amarenco P; Bokelund-Singh S; Denison H; Evans SR; Held P; Jahreskog M; Jonasson J; Minematsu K; Molina CA; Wang Y; Wong KSL; Johnston SC;
    Circulation; 2017 Sep; 136(10):907-916. PubMed ID: 28655834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
    Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects.
    De Filippo O; D'Ascenzo F; Raposeiras-Roubin S; Abu-Assi E; Peyracchia M; Bocchino PP; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Templin C; Wilton SB; Omedè P; Velicki L; Xanthopoulou I; Correia L; Cerrato E; Rognoni A; Fabrizio U; Nuñez-Gil I; Iannaccone M; Montabone A; Taha S; Fujii T; Durante A; Song X; Gili S; Magnani G; Varbella F; Kawaji T; Blanco PF; Garay A; Quadri G; Alexopoulos D; Caneiro Queija B; Huczek Z; Cobas Paz R; González Juanatey JR; Cespón Fernández M; Nie SP; Muñoz Pousa I; Kawashiri MA; Gallo D; Morbiducci U; Conrotto F; Montefusco A; Dominguez-Rodriguez A; López-Cuenca A; Cequier A; Iñiguez-Romo A; Usmiani T; Rinaldi M; De Ferrari GM
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):31-42. PubMed ID: 31511896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study.
    Cesaro A; Taglialatela V; Gragnano F; Moscarella E; Fimiani F; Conte M; Barletta V; Monda E; Limongelli G; Severino S; Cirillo P; Calabrò P
    J Cardiovasc Pharmacol; 2020 Aug; 76(2):173-180. PubMed ID: 32569017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
    Timmis A; Rapsomaniki E; Chung SC; Pujades-Rodriguez M; Moayyeri A; Stogiannis D; Shah AD; Pasea L; Denaxas S; Emmas C; Hemingway H
    BMJ; 2016 Jun; 353():i3163. PubMed ID: 27334486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
    Bhatt DL; Fox K; Harrington RA; Leiter LA; Mehta SR; Simon T; Andersson M; Himmelmann A; Ridderstråle W; Held C; Steg PG;
    Clin Cardiol; 2019 May; 42(5):498-505. PubMed ID: 30788847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
    Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.
    Gao R; Wu Y; Liu H; Su G; Yuan Z; Zhang A; Wang Y; Wang Z; Wang Y; Zhang H; Zheng Y; Liu L; Shen L; Leonsson-Zachrisson M; Han Y;
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):47-56. PubMed ID: 29488142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
    Cavallari I; Morrow DA; Creager MA; Olin J; Bhatt DL; Steg PG; Storey RF; Cohen M; Scirica BS; Piazza G; Goodrich EL; Braunwald E; Sabatine MS; Bonaca MP
    Circulation; 2018 Feb; 137(7):684-692. PubMed ID: 29084737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial.
    Kogame N; Chichareon P; De Wilder K; Takahashi K; Modolo R; Chang CC; Tomaniak M; Komiyama H; Chieffo A; Colombo A; Garg S; Louvard Y; Jüni P; G Steg P; Hamm C; Vranckx P; Valgimigli M; Windecker S; Stoll HP; Onuma Y; Janssens L; Serruys PW
    Catheter Cardiovasc Interv; 2020 Jul; 96(1):100-111. PubMed ID: 31410968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial.
    Gao C; Tomaniak M; Takahashi K; Kawashima H; Wang R; Hara H; Ono M; Montalescot G; Garg S; Haude M; Slagboom T; Vranckx P; Valgimigli M; Windecker S; van Geuns RJ; Hamm C; Steg PG; Onuma Y; Angiolillo DJ; Serruys PW
    Cardiovasc Diabetol; 2020 Oct; 19(1):179. PubMed ID: 33066794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
    Vranckx P; Valgimigli M; Jüni P; Hamm C; Steg PG; Heg D; van Es GA; McFadden EP; Onuma Y; van Meijeren C; Chichareon P; Benit E; Möllmann H; Janssens L; Ferrario M; Moschovitis A; Zurakowski A; Dominici M; Van Geuns RJ; Huber K; Slagboom T; Serruys PW; Windecker S;
    Lancet; 2018 Sep; 392(10151):940-949. PubMed ID: 30166073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
    Angiolillo DJ; Baber U; Sartori S; Briguori C; Dangas G; Cohen DJ; Mehta SR; Gibson CM; Chandiramani R; Huber K; Kornowski R; Weisz G; Kunadian V; Oldroyd KG; Ya-Ling H; Kaul U; Witzenbichler B; Dudek D; Sardella G; Escaned J; Sharma S; Shlofmitz RA; Collier T; Pocock S; Mehran R
    J Am Coll Cardiol; 2020 May; 75(19):2403-2413. PubMed ID: 32240760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
    Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
    Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.